✦ LIBER ✦

Investigation of the central mechanism of action required for antibody mediated phagocytosis of pre-existing plaque and the development of a novel antibody therapeutic for Alzheimer's disease

✍ Scribed by DeMattos, Ronald; Lu, Jirong; Tang, Ying; Racke, Margaret; DeLong, Cynthia; Jordan, William; Tzaferis, John; McDonnell, Peter; Hole, Justin; Hutton, Michael

Book ID: 122479154
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 57 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.09.106

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel recombinant human amyloid plaque

A novel recombinant human amyloid plaque-specific antibody for the treatment of Alzheimer's disease: Molecular properties and preclinical efficacy

✍ Bohrmann, Bernd; Benz, Joerg; Baumann, Karlheinz; Huber, Walter; Knoflach, Fred; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Research and development of anti-Aß olig

Research and development of anti-Aß oligomers antibodies for the treatment of Alzheimer's disease

✍ Yasuhide Okamoto; Tatsuki Yokoseki; Takamatsu Naofumi; Yukiho Imai; Shinobu Fuji 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Examining the role of ApoE in LXR-Mediat

Examining the role of ApoE in LXR-Mediated Aβ clearance mechanisms: Implications for the development of Alzheimer's disease therapeutics

✍ David Riddell 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 57 KB

P2-306: Activation of both LXRα and LXRβ

P2-306: Activation of both LXRα and LXRβ is required for TO901317-mediated lowering of Aβ42: implications for the development of Alzheimer's therapeutics

✍ Riddell, D.R.; Li, Z.; Zhou, H.; Aschmies, S.; Kouranova, E.; Ring, R.; Warwick, 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB